Tetherex raises $50M series B, plans Phase II for pan-selectin inhibitor
Tetherex Pharmaceuticals Inc. (Oklahoma City, Okla.) said it closed a $50 million series B round Wednesday led by existing investor MPM Capital. I2E, Tetherex board member Philip